Cancellation of Own Shares

RTW Biotech Opportunities Ltd

24 May 2024

 

LEI: 549300Q7EXQQH6KF7Z84

24 May 2024

RTW Biotech Opportunities Ltd

Cancellation of Own Shares

Following approval at the Annual General meeting held on 16 May 2024 the Company has today cancelled 48,322,863 of its own shares that were previously held by RTW Biotech Opportunities Operating Ltd ("RTW OpCo") for nil consideration. Such Shares were issued to RTW Opco pursuant to the scheme of reconstruction of Arix Bioscience plc ("Arix"), as described in the Company's prospectus dated 5 January 2024.

Further details are set out below:

Number of shares held as treasury shares following this cancellation: 9,853,791

Total shares in issue excluding treasury shares following this cancellation: 336,113,649

The above figure of 336,113,649 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

For Further Information:

RTW Investments, LP	[phone] [e-mail]
Woody Stileman, Managing Director Krisha McCune, Director, Investor Relations

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.

 

END